# Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati

Source: https://onco.cc/trials/nct07195695/  
OnCo record `nct07195695` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Zongertinib, Pembrolizumab, Atezolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Boehringer Ingelheim, now recruiting.

## Summary

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations is a phase 3 interventional study registered as NCT07195695 by Boehringer Ingelheim, with 400 participants planned, started 2026-01-16 and due to reach its primary completion in 2032-02-26. Interventions recorded: Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07195695
- Phase: 3
- Setting: Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations
- Sponsor: Boehringer Ingelheim
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT07195695: https://clinicaltrials.gov/study/NCT07195695

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Zongertinib](https://onco.cc/drugs/zongertinib/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/nct07195695.json